Atezolizumab plus cobimetinib and vemurafenib in BRAF-mutated melanoma patients

[1]  R. Sullivan,et al.  Analysis of the kinetics and effects of vemurafenib (V) + cobimetinib (C) on intratumoral and host immunity in patients (pts) with BRAFV600 mutant melanoma (BRAFmM): Implications for combination with immunotherapy. , 2018 .

[2]  R. Fisher,et al.  1216OKEYNOTE-022 update: phase 1 study of first-line pembrolizumab (pembro) plus dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma , 2017 .

[3]  P. Hegde,et al.  Gene Expression Profiling in BRAF-Mutated Melanoma Reveals Patient Subgroups with Poor Outcomes to Vemurafenib That May Be Overcome by Cobimetinib Plus Vemurafenib , 2017, Clinical Cancer Research.

[4]  N. Ibrahim,et al.  Impact of baseline serum lactate dehydrogenase concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006 , 2017 .

[5]  D. Schadendorf,et al.  Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials. , 2016, The Lancet. Oncology.

[6]  J. Lunceford,et al.  Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Matthew Wongchenko,et al.  Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. , 2016, The Lancet. Oncology.

[8]  R. Bourgon,et al.  Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial , 2016, The Lancet.

[9]  M. Belvin,et al.  MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade. , 2016, Immunity.

[10]  D. Samuel,et al.  Discrimination of cirrhotic nodules, dysplastic lesions and hepatocellular carcinoma by their vibrational signature , 2016, Journal of Translational Medicine.

[11]  J. Utikal,et al.  Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial , 2015, The Lancet.

[12]  Dirk Schadendorf,et al.  Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. , 2015, The New England journal of medicine.

[13]  J. Larkin,et al.  Pembrolizumab versus Ipilimumab in Advanced Melanoma. , 2015, The New England journal of medicine.

[14]  J. Lunceford,et al.  Pembrolizumab for the treatment of non-small-cell lung cancer. , 2015, The New England journal of medicine.

[15]  G. Linette,et al.  Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. , 2015, The Lancet. Oncology.

[16]  T. Graeber,et al.  Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma , 2015, Science Translational Medicine.

[17]  H. Kohrt,et al.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.

[18]  P. Ascierto,et al.  Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. , 2014, The New England journal of medicine.

[19]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[20]  G. Freeman,et al.  Response to BRAF Inhibition in Melanoma Is Enhanced When Combined with Immune Checkpoint Blockade , 2014, Cancer Immunology Research.

[21]  J. Cebon,et al.  MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells , 2014, Cancer Immunology Research.

[22]  David E Fisher,et al.  BRAF inhibition is associated with increased clonality in tumor-infiltrating lymphocytes , 2013, Oncoimmunology.

[23]  J. Wilmott,et al.  Effects of BRAF inhibitors on human melanoma tissue before treatment, early during treatment, and on progression , 2013, Pigment cell & melanoma research.

[24]  B. Schilling,et al.  Immunological consequences of selective BRAF inhibitors in malignant melanoma , 2013, Oncoimmunology.

[25]  R. Sullivan,et al.  BRAF Inhibition Is Associated with Enhanced Melanoma Antigen Expression and a More Favorable Tumor Microenvironment in Patients with Metastatic Melanoma , 2013, Clinical Cancer Research.

[26]  C. Hill,et al.  Vemurafenib enhances MHC induction in BRAFV600E homozygous melanoma cells , 2013, Oncoimmunology.

[27]  Dennie T. Frederick,et al.  Oncogenic BRAF(V600E) Promotes Stromal Cell-Mediated Immunosuppression Via Induction of Interleukin-1 in Melanoma , 2012, Clinical Cancer Research.

[28]  A. Hauschild,et al.  Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial , 2012, The Lancet.

[29]  F. Marincola,et al.  The role of BRAF V600 mutation in melanoma , 2012, Journal of Translational Medicine.

[30]  J. Wilmott,et al.  Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma , 2011, Clinical Cancer Research.

[31]  A. Hauschild,et al.  Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.

[32]  D. Schadendorf,et al.  Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.

[33]  K. Flaherty,et al.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function. , 2010, Cancer research.

[34]  I. S. Dunn,et al.  Role of the Mitogen-Activated Protein Kinase Signaling Pathway in the Regulation of Human Melanocytic Antigen Expression , 2006, Molecular Cancer Research.

[35]  Y. Kawakami,et al.  The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells , 2006, The Journal of experimental medicine.

[36]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[37]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[38]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[39]  A. Hauschild,et al.  Improved overall survival in melanoma with combined dabrafenib and trametinib. , 2015, The New England journal of medicine.